Putera Azwin Mengindra, Hikmah Zahrah, Endaryanto Anang, Maramis Margarita Maria
Department of Child Health, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Department of Psychiatry, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Heliyon. 2021 Mar 16;7(3):e06510. doi: 10.1016/j.heliyon.2021.e06510. eCollection 2021 Mar.
Chronic rhinosinusitis allergy (CRA) is a disease that is commonly found in children and is mostly caused by allergy to house dust mites (HDM). The use of HDM immunotherapy can be considered in children with allergies.
Analyzing the impact of mite immunotherapy on disease burden in Indonesian children with CRA.
A randomized control trial study was conducted to participants in 2 groups, namely the immunotherapy group (n = 25) and the non-immunotherapy group (n = 25). Participants were given HDM immunotherapy for 14 weeks, which was given once per week. Participants during therapy were evaluated for rhinosinusitis symptoms and measured their immunity status (specific IgE), sleep quality (SDSC), quality of life (SN5), and family coping (F-COPES) pre-post therapy. Statistical analysis used in this study included paired t-test, Wilcoxon test, independent t-test, or Mann Whitney test with < 0.05.
The value of specific IgE in the immunotherapy group was 4.12 ± 7.75 kU/l (pre-test) and 1.52 ± 2.42 kU/l (post-test; < 0.001), while in the non-immunotherapy group was 1.47 ± 3.28 kU/l (pre-test) and 1.18 ± 2.81 kU/l (post-test; = 0.317). The SDSC value in the immunotherapy group was 42.16 ± 2.75 (pre-test) and 30.32 ± 3.22 (post-test; < 0.001), while in the non-immunotherapy group was 41.92 ± 2.75 (pre-test) and 41.84 ± 2.87 (post-test; = 0.987). The F-COPES value in the immunotherapy group was 101.56 ± 5.78 (pre-test) and 105.20 ± 4.31 (post-test; = 0.015), while in the non-immunotherapy group was 100.36 ± 9.63 (pre-test) and 99.96 ± 9.98 (post-test; p = 0.224). The SN-5 value in the immunotherapy group was 30.04 ± 2.78 (pre-test) and 11.00 ± 2.33 (post-test; < 0.001), while in the non-immunotherapy group was 30.04 ± 2.78 (pre-test) and 30.04 ± 2.78 (post-test; = 0.767). There was a significant comparison between the immunotherapy group and the non-immunotherapy group on the specific IgE ( = 0.013), SDSC ( < 0.001), and SN-5 ( < 0.001) values. Meanwhile, there was no significant difference in the F-COPES value ( = 0.129).
The administration of HDM immunotherapy can improve the participant's immunity, quality of life, and sleep disorder.
慢性鼻窦炎伴过敏（CRA）是一种常见于儿童的疾病，主要由对屋尘螨（HDM）过敏引起。对于过敏儿童可考虑采用HDM免疫疗法。
分析螨免疫疗法对印度尼西亚CRA儿童疾病负担的影响。
对两组参与者进行随机对照试验研究，即免疫疗法组（n = 25）和非免疫疗法组（n = 25）。参与者接受14周的HDM免疫疗法，每周给药一次。在治疗期间评估参与者的鼻窦炎症状，并在治疗前后测量其免疫状态（特异性IgE）、睡眠质量（SDSC）、生活质量（SN5）和家庭应对能力（F-COPES）。本研究中使用的统计分析包括配对t检验、Wilcoxon检验、独立t检验或Mann-Whitney检验，P<0.05。
免疫疗法组的特异性IgE值在治疗前为4.12±7.75 kU/l，治疗后为1.52±2.42 kU/l（P<0.001）；而非免疫疗法组治疗前为1.47±3.28 kU/l，治疗后为1.18±2.81 kU/l（P = 0.317）。免疫疗法组的SDSC值治疗前为42.16±2.75，治疗后为30.32±3.22（P<0.001）；非免疫疗法组治疗前为41.92±2.75，治疗后为41.84±2.87（P = 0.987）。免疫疗法组的F-COPES值治疗前为101.56±5.78，治疗后为105.20±4.31（P = 0.015）；非免疫疗法组治疗前为100.36±9.63，治疗后为99.96±9.98（P = 0.224）。免疫疗法组的SN-5值治疗前为30.04±2.78，治疗后为11.00±2.33（P<0.001）；非免疫疗法组治疗前为30.04±2.78，治疗后为30.04±2.78（P = 0.767）。免疫疗法组与非免疫疗法组在特异性IgE（P = 0.013）、SDSC（P<0.001）和SN-5（P<0.001）值上存在显著差异。同时，F-COPES值无显著差异（P = 0.129）。
给予HDM免疫疗法可改善参与者的免疫力、生活质量和睡眠障碍。
